StockData
HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3

HAEMONETICS CORP

Financials through Q1 FY2027, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 6, 2026
$118.73+0.45 (+0.38%)

Close on Oct 19, 2026

Market cap
$5.43B
P/E (TTM)
57.9
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q1 FY2027
Ended Jun 27, 2026
Aug 6, 2026Before market open$339.40M$0.72$1.14
Q4 FY2026
Ended Mar 28, 2026
May 7, 2026Before market open$346.40M$-0.44$1.29
Q3 FY2026
Ended Dec 27, 2025
Feb 5, 2026Before market open$339.00M$0.95$1.31
Q2 FY2026
Ended Sep 27, 2025
Nov 6, 2025Before market open$327.30M$0.81$1.27
Q1 FY2026
Ended Jun 28, 2025
Aug 7, 2025Before market open$321.40M$0.70$1.10
Q4 FY2025
Ended Mar 29, 2025
May 8, 2025Before market open$330.60M$1.17$1.24
Q3 FY2025
Ended Dec 28, 2024
Feb 6, 2025Before market open$348.50M$0.74$1.19
Q2 FY2025
Ended Sep 28, 2024
Nov 7, 2024Before market open$345.50M$0.66$1.12
Q1 FY2025
Ended Jun 29, 2024
Aug 8, 2024Before market open–––
Q4 FY2024
Ended Mar 30, 2024
May 9, 2024Before market open–––
Q3 FY2024
Ended Dec 30, 2023
Feb 8, 2024Before market open–––

Company guidance

Outlook given with results on May 7, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Free cash flow conversionnon-GAAPfiscal 202780%New
Organic Revenuenon-GAAPfiscal 20273% to 6% growthNew
Reported RevenueGAAPfiscal 20274% to 7% growthNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Haemonetics filed with the SEC